Excision BioTherapeutics has licensed recently discovered CRISPR gene editors from UC Berkeley. The deal gives Excision the exclusive right to use the Cas9 alternatives to treat infectious diseases.
A CRISPR-Cas9 gene editing technology that has shown promise in clearing HIV from mice is headed into human testing. Excision BioTherapeutics will usher the CRISPR-based therapy EBT-101 into clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results